|
ES2390425T3
(es)
|
2000-12-22 |
2012-11-12 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Uso de moléculas de orientación repulsivas (RGM) y sus moduladores
|
|
EP1228766A1
(en)
*
|
2001-01-31 |
2002-08-07 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
PYK2 phosphorylation by HER3 induces tumor invasion
|
|
TWI229650B
(en)
*
|
2002-11-19 |
2005-03-21 |
Sharp Kk |
Substrate accommodating tray
|
|
US8759490B2
(en)
|
2005-03-24 |
2014-06-24 |
Millennium Pharamaceuticals, Inc. |
Antibodies that bind OV064 and methods of use therefor
|
|
EP3058955B1
(en)
*
|
2005-03-24 |
2019-05-29 |
Millennium Pharmaceuticals, Inc. |
Antibodies that bind ov064 and methods of use therefor
|
|
CN101277974A
(zh)
|
2005-09-30 |
2008-10-01 |
阿伯特有限及两合公司 |
排斥性引导分子(rgm)蛋白质家族的蛋白质的结合结构域及其功能性片段和它们的用途
|
|
AU2015201263B2
(en)
*
|
2005-12-30 |
2017-01-12 |
Amgen Inc. |
Material and methods for treating or preventing her-3 associated diseases
|
|
AR056857A1
(es)
|
2005-12-30 |
2007-10-24 |
U3 Pharma Ag |
Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
|
|
JP5656406B2
(ja)
*
|
2006-11-28 |
2015-01-21 |
ユースリー ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツングＵ３ Ｐｈａｒｍａ ＧｍｂＨ |
治療効力を予測するためのマーカーとしての活性化ｈｅｒ３
|
|
SG178789A1
(en)
*
|
2007-02-16 |
2012-03-29 |
Merrimack Pharmaceuticals Inc |
Antibodies against erbb3 and uses thereof
|
|
BRPI0809435A2
(pt)
|
2007-03-27 |
2014-09-09 |
Sea Lane Biotechnologies, Llc |
Constructos e bibliotecas que compreendem sequências de cadeia leve substituida de anticorpos
|
|
EP1997830A1
(en)
|
2007-06-01 |
2008-12-03 |
AIMM Therapeutics B.V. |
RSV specific binding molecules and means for producing them
|
|
US8962803B2
(en)
|
2008-02-29 |
2015-02-24 |
AbbVie Deutschland GmbH & Co. KG |
Antibodies against the RGM A protein and uses thereof
|
|
BRPI0910482A2
(pt)
|
2008-04-29 |
2019-09-24 |
Abbott Lab |
imunoglobinas de domínio variável duplo e usos das mesmas
|
|
WO2009151908A1
(en)
*
|
2008-05-25 |
2009-12-17 |
Wyeth |
Biomarkers for egfr/her/erbb drug efficacy
|
|
BRPI0913366A8
(pt)
|
2008-06-03 |
2017-07-11 |
Abbott Lab |
Imunoglobulinas de domínio variável duplo e seus usos
|
|
EP2138511A1
(en)
*
|
2008-06-27 |
2009-12-30 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
HER3 as a determinant for the prognosis of melanoma
|
|
NZ603698A
(en)
|
2008-07-08 |
2014-03-28 |
Abbvie Inc |
Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
|
|
AU2013202396B2
(en)
*
|
2008-07-16 |
2014-07-10 |
Institute For Research In Biomedicine |
Human cytomegalovirus neutralizing antibodies and use thereof
|
|
UA104868C2
(uk)
*
|
2008-08-15 |
2014-03-25 |
Меррімак Фармасьютікалз, Інк. |
Спосіб лікування пацієнта, що має неопластичну пухлину, відповідно до спрогнозованої реакції
|
|
AU2009308707A1
(en)
|
2008-10-31 |
2010-05-06 |
Biogen Idec Ma Inc. |
LIGHT targeting molecules and uses thereof
|
|
WO2010085845A1
(en)
*
|
2009-01-28 |
2010-08-05 |
The University Of Queensland |
Cancer therapy and/or diagnosis
|
|
CN102326081B
(zh)
*
|
2009-02-24 |
2014-11-19 |
霍夫曼-拉罗奇有限公司 |
s-ErbB-3作为癌症标志物的应用
|
|
CN104447995A
(zh)
|
2009-03-20 |
2015-03-25 |
霍夫曼-拉罗奇有限公司 |
双特异性抗-her抗体
|
|
MX2011010166A
(es)
|
2009-04-07 |
2011-10-11 |
Roche Glycart Ag |
Anticuerpos biespecificos anti-erbb-3/anti-c-met.
|
|
AU2010242914B2
(en)
*
|
2009-04-29 |
2014-11-13 |
Trellis Bioscience, Llc |
Improved antibodies immunoreactive with heregulin-coupled HER3
|
|
CN102482345A
(zh)
|
2009-05-13 |
2012-05-30 |
航道生物技术有限责任公司 |
针对流感病毒的中和分子
|
|
WO2011004899A1
(en)
*
|
2009-07-06 |
2011-01-13 |
Takeda Pharmaceutical Company Limited |
Cancerous disease modifying antibodies
|
|
KR20120060877A
(ko)
|
2009-09-01 |
2012-06-12 |
아보트 러보러터리즈 |
이원 가변 도메인 면역글로불린 및 이의 용도
|
|
JP2013507378A
(ja)
*
|
2009-10-09 |
2013-03-04 |
メルク・シャープ・エンド・ドーム・コーポレイション |
抗ｈｅｒ３抗体の製造、特徴づけ及びその用途
|
|
AU2010306677B2
(en)
|
2009-10-15 |
2013-05-23 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
|
MY173390A
(en)
*
|
2009-10-23 |
2020-01-22 |
Takeda Pharmaceuticals Co |
Anti-gcc antibody molecules and related compositions and methods
|
|
UY32979A
(es)
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
EP2494046B1
(en)
|
2009-10-30 |
2018-09-12 |
Novartis AG |
Universal fibronectin type iii bottom-side binding domain libraries
|
|
MX358013B
(es)
*
|
2009-11-13 |
2018-08-01 |
Amgen Inc |
Materiales y metodos para el tratamiento o prevencion de enfermedades asociadas al her-3.
|
|
CN102656190A
(zh)
|
2009-12-08 |
2012-09-05 |
雅培股份有限两合公司 |
用于在视网膜神经纤维层变性治疗中使用的针对rgm a蛋白质的单克隆抗体
|
|
MA33892B1
(fr)
*
|
2009-12-22 |
2013-01-02 |
Roche Glycart Ag |
Anticorps anti-her3, et leurs utilisations
|
|
ES2602971T3
(es)
|
2010-03-02 |
2017-02-23 |
Kyowa Hakko Kirin Co., Ltd. |
Composición de anticuerpo modificado
|
|
CA2792327C
(en)
|
2010-03-11 |
2019-09-24 |
Merrimack Pharmaceuticals, Inc. |
Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers
|
|
CN102884085B
(zh)
|
2010-04-09 |
2016-08-03 |
Aveo制药公司 |
抗erbb3抗体
|
|
CN102906118B
(zh)
|
2010-05-20 |
2017-07-28 |
埃博灵克斯股份有限公司 |
与her3相关的生物材料
|
|
EP2590654B1
(en)
|
2010-07-09 |
2016-12-21 |
Exelixis, Inc. |
Combinations of kinase inhibitors for the treatment of cancer
|
|
CN107903321A
(zh)
|
2010-07-30 |
2018-04-13 |
诺华有限公司 |
纤连蛋白摇篮分子和其库
|
|
US8735546B2
(en)
|
2010-08-03 |
2014-05-27 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
|
WO2012019024A2
(en)
*
|
2010-08-04 |
2012-02-09 |
Immunogen, Inc. |
Her3-binding molecules and immunoconjugates thereof
|
|
AU2011286407A1
(en)
*
|
2010-08-06 |
2013-02-21 |
Amgen |
Use of HER3 binding agents in prostate treatment
|
|
NZ607337A
(en)
*
|
2010-08-20 |
2015-06-26 |
Novartis Ag |
Antibodies for epidermal growth factor receptor 3 (her3)
|
|
PE20140229A1
(es)
|
2010-08-26 |
2014-03-27 |
Abbvie Inc |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
TW201302793A
(zh)
*
|
2010-09-03 |
2013-01-16 |
Glaxo Group Ltd |
新穎之抗原結合蛋白
|
|
IT1402149B1
(it)
*
|
2010-10-04 |
2013-08-28 |
Ist Fisioterap Ospitalroma |
Uso di un fosfopeptide in grado di bloccare l interazione her3/p85 per il trattamento dei tumori iperesprimenti her2.
|
|
EP2630160B1
(en)
*
|
2010-10-18 |
2016-11-09 |
MediaPharma S.r.l. |
Erbb3 binding antibody
|
|
JP6033783B2
(ja)
*
|
2010-11-01 |
2016-11-30 |
シムフォゲン・アクティーゼルスカブＳｙｍｐｈｏｇｅｎ Ａ／Ｓ |
Ｐａｎ−ｈｅｒ抗体組成物
|
|
US9155802B2
(en)
|
2010-11-01 |
2015-10-13 |
Symphogen A/S |
Pan-HER antibody composition
|
|
ITRM20100577A1
(it)
|
2010-11-02 |
2012-05-03 |
Takis Srl |
Immunoterapia contro il recettore erbb-3
|
|
AU2011342161C1
(en)
|
2010-12-15 |
2016-03-17 |
Kyowa Kirin Co., Ltd. |
Process for production of protein
|
|
ES2738867T3
(es)
*
|
2010-12-29 |
2020-01-27 |
Expression Pathology Inc |
Análisis cuantitativo de la proteína Her3 mediante SRM/MRM
|
|
US20140134170A1
(en)
|
2011-03-11 |
2014-05-15 |
Merrimack Pharmaceuticals, Inc. |
Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers
|
|
SG192775A1
(en)
|
2011-03-15 |
2013-09-30 |
Merrimack Pharmaceuticals Inc |
Overcoming resistance to erbb pathway inhibitors
|
|
UA117218C2
(uk)
|
2011-05-05 |
2018-07-10 |
Мерк Патент Гмбх |
Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
|
|
NO2707391T3
(https=)
|
2011-05-13 |
2018-04-07 |
|
|
|
KR102101806B1
(ko)
*
|
2011-05-19 |
2020-04-20 |
인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) |
항-인간-her3 항체 및 이의 용도
|
|
AU2012274461A1
(en)
|
2011-06-20 |
2014-01-16 |
Kyowa Hakko Kirin Co., Ltd. |
Anti-erbB3 antibody
|
|
WO2013016714A1
(en)
*
|
2011-07-28 |
2013-01-31 |
Sea Lane Biotechnologies |
Sur-binding proteins against erbb3
|
|
EP2748197A2
(en)
|
2011-08-26 |
2014-07-02 |
Merrimack Pharmaceuticals, Inc. |
Tandem fc bispecific antibodies
|
|
HK1200468A1
(en)
*
|
2011-09-30 |
2015-08-07 |
Regeneron Pharmaceuticals, Inc. |
Anti-erbb3 antibodies and uses thereof
|
|
US9273143B2
(en)
|
2011-09-30 |
2016-03-01 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody
|
|
US9828635B2
(en)
|
2011-10-06 |
2017-11-28 |
Aveo Pharmaceuticals, Inc. |
Predicting tumor response to anti-ERBB3 antibodies
|
|
EP2773659A2
(en)
|
2011-10-31 |
2014-09-10 |
Bristol-Myers Squibb Company |
Fibronectin binding domains with reduced immunogenicity
|
|
AU2012335543C1
(en)
|
2011-11-09 |
2017-12-14 |
Beijing Cotimes Biotech Co., Ltd., |
HER3 antibodies and uses thereof
|
|
JP6180425B2
(ja)
|
2011-11-23 |
2017-08-23 |
メディミューン，エルエルシー |
Ｈｅｒ３に特異的な結合分子及びそれらの使用
|
|
AU2012349735B2
(en)
*
|
2011-12-05 |
2016-05-19 |
Novartis Ag |
Antibodies for epidermal growth factor receptor 3 (HER3)
|
|
EA201491120A1
(ru)
*
|
2011-12-05 |
2015-07-30 |
Новартис Аг |
Антитела к рецептору эпидермального фактора роста 3 (her3), направленные на домен iii и домен iv her3
|
|
KR20140103135A
(ko)
*
|
2011-12-05 |
2014-08-25 |
노파르티스 아게 |
Her3의 도메인 ii에 대해 지시된 표피 성장 인자 수용체 3 (her3)에 대한 항체
|
|
EP3446707A1
(en)
|
2011-12-22 |
2019-02-27 |
i2 Pharmaceuticals, Inc. |
Surrogate binding proteins
|
|
AR089529A1
(es)
|
2011-12-30 |
2014-08-27 |
Abbvie Inc |
Proteinas de union especificas duales dirigidas contra il-13 y/o il-17
|
|
NZ714482A
(en)
|
2012-01-27 |
2017-08-25 |
Abbvie Inc |
Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
|
|
ES2842201T3
(es)
*
|
2012-02-23 |
2021-07-13 |
Daiichi Sankyo Europe Gmbh |
Inhibidor de HER3 para modulación de radiosensibilidad
|
|
RU2014136886A
(ru)
|
2012-03-27 |
2016-05-20 |
Дженентек, Инк. |
Диагностика и виды лечения, связанные с ингибиторами her3
|
|
ME03560B
(me)
|
2012-04-27 |
2020-07-20 |
Millennium Pharm Inc |
MOLEKULI ANTI-GCC ANTITELA l NJIHOVA UPOTREBA U ISPITIVANJU OSETLJIVOSTI NA GCC-CILJANU TERAPIJU
|
|
EP2844675B1
(en)
*
|
2012-05-02 |
2019-01-02 |
Symphogen A/S |
Humanized pan-her antibody compositions
|
|
CA2886036A1
(en)
|
2012-09-25 |
2014-04-03 |
Ichnos Sciences SA |
Purification of hetero-dimeric immunoglobulins
|
|
EP2912066A4
(en)
|
2012-10-25 |
2016-10-12 |
Sorrento Therapeutics Inc |
ANTIGENBINDING PROTEINS FOR BINDING ERBB3
|
|
KR20180008921A
(ko)
|
2012-11-01 |
2018-01-24 |
애브비 인코포레이티드 |
항-ｖｅｇｆ／ｄｌｌ4 이원 가변 도메인 면역글로불린 및 이의 용도
|
|
US9725511B2
(en)
|
2012-11-08 |
2017-08-08 |
Hoffmann-La Roche Inc. |
Anti-HER3/HER4 antibodies binding to the beta-hairpin of HER3 and the beta-hairpin of HER4
|
|
MX2015005757A
(es)
|
2012-11-08 |
2015-11-18 |
Hoffmann La Roche |
Proteinas ligantes de antigeno her3 de union a la horquilla beta de her3.
|
|
UY35148A
(es)
|
2012-11-21 |
2014-05-30 |
Amgen Inc |
Immunoglobulinas heterodiméricas
|
|
US9180185B2
(en)
|
2013-01-11 |
2015-11-10 |
Hoffman-La Roche Inc. |
Combination therapy of anti-HER3 antibodies
|
|
TW201444872A
(zh)
|
2013-03-06 |
2014-12-01 |
Merrimack Pharmaceuticals Inc |
抗Ｃ－ＭＥＴ串聯Ｆｃ雙特異性抗體
|
|
CN105209493B
(zh)
*
|
2013-03-14 |
2019-05-03 |
德克萨斯州大学系统董事会 |
用于诊断和治疗用途的her3特异性单克隆抗体
|
|
JP2016515132A
(ja)
|
2013-03-14 |
2016-05-26 |
ジェネンテック， インコーポレイテッド |
Ｍｅｋ阻害剤化合物のｈｅｒ３／ｅｇｆｒ阻害剤化合物との組み合わせ及び使用方法
|
|
WO2014144817A2
(en)
|
2013-03-15 |
2014-09-18 |
Amgen Inc. |
Inhibitory polypeptides specific to wnt inhibitors
|
|
CN105324396A
(zh)
|
2013-03-15 |
2016-02-10 |
艾伯维公司 |
针对IL-1β和/或IL-17的双重特异性结合蛋白
|
|
EP2821071A1
(en)
|
2013-07-04 |
2015-01-07 |
Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) |
Compounds for breast cancer treatment
|
|
TW201605896A
(zh)
|
2013-08-30 |
2016-02-16 |
安美基股份有限公司 |
Gitr抗原結合蛋白
|
|
EP3712166A1
(en)
|
2013-09-05 |
2020-09-23 |
Amgen Inc. |
Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
|
|
US11305012B2
(en)
|
2013-09-24 |
2022-04-19 |
Medimmune, Llc |
Binding molecules specific for HER3 and uses thereof
|
|
WO2015066543A1
(en)
*
|
2013-11-01 |
2015-05-07 |
Board Of Regents, The University Of Texas System |
Targeting her2 and her3 with bispecific antibodies in cancerous cells
|
|
CA2929386C
(en)
|
2013-11-07 |
2023-01-03 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Neuregulin allosteric anti-her3 antibody
|
|
EP3087394A2
(en)
|
2013-12-27 |
2016-11-02 |
Merrimack Pharmaceuticals, Inc. |
Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
|
|
AU2015229591B2
(en)
|
2014-03-11 |
2020-10-22 |
Regeneron Pharmaceuticals, Inc. |
Anti-EGFRvlll antibodies and uses thereof
|
|
KR102399277B1
(ko)
|
2014-04-10 |
2022-05-18 |
다이이찌 산쿄 가부시키가이샤 |
항her3 항체-약물 콘주게이트
|
|
US10745490B2
(en)
|
2014-04-11 |
2020-08-18 |
Celldex Therapeutics, Inc. |
Anti-ErbB antibodies and methods of use thereof
|
|
FR3020063A1
(fr)
|
2014-04-16 |
2015-10-23 |
Gamamabs Pharma |
Anticorps humain anti-her4
|
|
MX2016014416A
(es)
|
2014-05-14 |
2017-02-23 |
Hoffmann La Roche |
Anticuerpos anti-her3 que se unen a la horquilla beta de her3.
|
|
US10156562B2
(en)
|
2014-05-16 |
2018-12-18 |
Amgen Inc. |
Assay for detecting Th1 and Th2 cell populations
|
|
WO2016059602A2
(en)
|
2014-10-16 |
2016-04-21 |
Glaxo Group Limited |
Methods of treating cancer and related compositions
|
|
WO2016094881A2
(en)
|
2014-12-11 |
2016-06-16 |
Abbvie Inc. |
Lrp-8 binding proteins
|
|
ES2884844T3
(es)
*
|
2015-03-09 |
2021-12-13 |
Agensys Inc |
Conjugados de anticuerpo fármaco (ADC) que se unen a proteínas FLT3
|
|
EP3091033A1
(en)
|
2015-05-06 |
2016-11-09 |
Gamamabs Pharma |
Anti-human-her3 antibodies and uses thereof
|
|
US10184006B2
(en)
|
2015-06-04 |
2019-01-22 |
Merrimack Pharmaceuticals, Inc. |
Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
|
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
|
|
EP4180455A1
(en)
|
2015-06-29 |
2023-05-17 |
Daiichi Sankyo Company, Limited |
Method for selectively manufacturing antibody-drug conjugate
|
|
TW201716439A
(zh)
|
2015-07-20 |
2017-05-16 |
美國禮來大藥廠 |
Ｈｅｒ３抗體
|
|
US20220313841A1
(en)
*
|
2015-09-02 |
2022-10-06 |
Sanford Burnham Prebys Medical Discovery Institute |
Compositions and methods for treating nervous system injuries
|
|
JP2018536682A
(ja)
|
2015-12-11 |
2018-12-13 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
Ｅｇｆｒ及び／またはｅｒｂｂ３遮断に耐性のある腫瘍の成長を低減または防止するための方法
|
|
KR20180119570A
(ko)
|
2016-03-15 |
2018-11-02 |
메리맥 파마슈티컬즈, 인크. |
항-ErbB3 항체를 포함하는 병용 요법을 이용한 ER+, HER2-, HRG+ 유방암의 치료
|
|
JP7145374B2
(ja)
*
|
2016-03-18 |
2022-10-03 |
ラトガース ザ ステイト ユニバーシティー オブ ニュージャージー |
インビボでの切断可能連結部分によって抗マトリプターゼ抗体にコンジュゲートされた化学療法剤を用いる腫瘍細胞の標的化
|
|
EA201991353A1
(ru)
|
2016-12-09 |
2019-11-29 |
|
Двухвалентные антитела, маскированные спирализованными спиралями
|
|
BR112019011794A2
(pt)
|
2016-12-12 |
2019-10-29 |
Daiichi Sankyo Co Ltd |
composição farmacêutica, e, método terapêutico.
|
|
CA3050668C
(en)
|
2017-01-17 |
2023-08-15 |
Daiichi Sankyo Company, Limited |
Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate
|
|
KR20240074000A
(ko)
|
2017-02-28 |
2024-05-27 |
다이이찌 산쿄 가부시키가이샤 |
항 her3 항체-약물 콘주게이트 투여에 의한 egfr-tki 저항성의 비소세포 폐암의 치료 방법
|
|
AU2018235928B2
(en)
|
2017-03-14 |
2023-09-21 |
Amgen Inc. |
Control of total afucosylated glycoforms of antibodies produced in cell culture
|
|
TW202532102A
(zh)
|
2017-05-15 |
2025-08-16 |
日商第一三共股份有限公司 |
抗體－藥物結合物及其用途
|
|
EP3673918A4
(en)
|
2017-08-23 |
2021-05-19 |
Daiichi Sankyo Company, Limited |
PREPARATION OF AN ANTIBODY INGREDIENT CONJUGATE AND LYOPHILIZATION FOR IT
|
|
BR112020003466B1
(pt)
|
2017-08-31 |
2023-12-12 |
Daiichi Sankyo Company, Limited |
Métodos de produção de composto, e, composto
|
|
ES3057444T3
(en)
|
2017-08-31 |
2026-03-02 |
Daiichi Sankyo Co Ltd |
Improved method for producing antibody-drug conjugate
|
|
EP3758751A4
(en)
|
2018-02-28 |
2021-11-17 |
Wuxi Biologics Ireland Limited. |
MONOCLONAL ANTIBODIES AGAINST HUMAN LAG-3, METHOD OF MANUFACTURING AND USING THEREOF
|
|
CN120463807A
(zh)
|
2018-03-22 |
2025-08-12 |
表面肿瘤学有限责任公司 |
抗il-27抗体及其用途
|
|
BR112020019559A2
(pt)
|
2018-03-26 |
2021-01-12 |
Amgen Inc. |
Glicoformas afucosiladas totais de anticorpos produzidos em cultura de células
|
|
WO2019210144A1
(en)
*
|
2018-04-27 |
2019-10-31 |
Vanderbilt University |
Broadly neutralizing antibodies against hepatitis c virus
|
|
HUE067382T2
(hu)
|
2018-05-18 |
2024-10-28 |
Daiichi Sankyo Co Ltd |
Anti-MUC1-exatecan antitest-hatóanyag konjugátum
|
|
CA3107417C
(en)
|
2018-07-25 |
2023-10-17 |
Daiichi Sankyo Company, Limited |
Effective method for manufacturing antibody-drug conjugate
|
|
TWI846717B
(zh)
|
2018-07-27 |
2024-07-01 |
日商第一三共股份有限公司 |
辨識抗體-藥物結合物之藥物部位的蛋白質
|
|
TW202537643A
(zh)
|
2018-07-31 |
2025-10-01 |
日商第一三共股份有限公司 |
抗體-藥物結合物之用途
|
|
TW202019487A
(zh)
|
2018-08-06 |
2020-06-01 |
日商第一三共股份有限公司 |
抗體-藥物結合物及微管蛋白抑制劑之組合
|
|
US12312641B2
(en)
|
2018-08-23 |
2025-05-27 |
Daiichi Sankyo Company, Limited |
Sensitivity marker for antibody-drug conjugate
|
|
CA3112043A1
(en)
|
2018-09-10 |
2020-03-19 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
KR20210062005A
(ko)
|
2018-09-20 |
2021-05-28 |
다이이찌 산쿄 가부시키가이샤 |
항 her3 항체-약물 콘쥬게이트 투여에 의한 her3 변이암의 치료
|
|
CN111289748A
(zh)
*
|
2018-12-08 |
2020-06-16 |
惠州市中大惠亚医院 |
ErbB3蛋白在制备膀胱癌无创诊断产品中的应用
|
|
WO2020122034A1
(ja)
|
2018-12-11 |
2020-06-18 |
第一三共株式会社 |
抗体－薬物コンジュゲートとｐａｒｐ阻害剤の組み合わせ
|
|
KR20210104094A
(ko)
*
|
2018-12-12 |
2021-08-24 |
우시 바이올로직스 아일랜드 리미티드 |
항-tim-3 항체 및 이의 용도
|
|
BR112021011393A2
(pt)
*
|
2018-12-13 |
2021-08-31 |
Surface Oncology, Inc. |
Anticorpos anti-il-27 e usos dos mesmos
|
|
JPWO2020130125A1
(ja)
|
2018-12-21 |
2021-11-04 |
第一三共株式会社 |
抗体−薬物コンジュゲートとキナーゼ阻害剤の組み合わせ
|
|
MX2022003461A
(es)
|
2019-09-26 |
2022-04-19 |
Amgen Inc |
Metodos de produccion de composiciones de anticuerpos.
|
|
EP4051711A4
(en)
*
|
2019-11-01 |
2024-02-21 |
Magenta Therapeutics, Inc. |
ANTI-CD45 ANTIBODIES AND THEIR CONJUGATES
|
|
AU2021210987A1
(en)
*
|
2020-01-24 |
2022-08-04 |
Regeneron Pharmaceuticals, Inc. |
Protein-antiviral compound conjugates
|
|
KR20210095781A
(ko)
|
2020-01-24 |
2021-08-03 |
주식회사 에이프릴바이오 |
항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
|
|
US11896619B2
(en)
*
|
2020-03-10 |
2024-02-13 |
Massachusetts Institute Of Technology |
Compositions and methods for immunotherapy of NPM1c-positive cancer
|
|
CN111282165B
(zh)
*
|
2020-03-18 |
2025-03-21 |
核工业总医院 |
放射治疗定位显影液及定位显影标记敷贴
|
|
WO2021247892A1
(en)
|
2020-06-04 |
2021-12-09 |
Amgen Inc. |
Assessment of cleaning procedures of a biotherapeutic manufacturing process
|
|
CN116133694B
(zh)
|
2020-10-14 |
2026-03-06 |
苏州盛迪亚生物医药有限公司 |
抗her3抗体和抗her3抗体药物偶联物及其医药用途
|
|
AU2021360897A1
(en)
|
2020-10-15 |
2023-05-25 |
Amgen Inc. |
Relative unpaired glycans in antibody production methods
|
|
AU2021378152A1
(en)
|
2020-11-11 |
2023-06-22 |
Daiichi Sankyo Company, Limited |
COMBINATION OF AN ANTIBODY-DRUG CONJUGATE WITH ANTI-SIRPα ANTIBODY
|
|
JP2023550462A
(ja)
*
|
2020-11-20 |
2023-12-01 |
アクティニウム ファーマシューティカルズ インコーポレイテッド |
固形がんの治療のためのｈｅｒ３放射免疫治療薬
|
|
US12551584B1
(en)
|
2020-12-07 |
2026-02-17 |
Actinium Pharmaceuticals, Inc. |
Lewis Y radioimmunotherapy for the treatment of cancer
|
|
EP4317549A4
(en)
|
2021-03-31 |
2025-03-26 |
Ddbio. Co, Ltd., (Shang Hai) |
Vector and method for screening functional antigen-binding protein
|
|
CN117241834A
(zh)
|
2021-04-29 |
2023-12-15 |
上海汇连生物医药有限公司 |
抗体偶联药物的制备方法及应用
|
|
EP4352094A1
(en)
|
2021-06-07 |
2024-04-17 |
Amgen Inc. |
Using fucosidase to control afucosylation level of glycosylated proteins
|
|
AU2022293634A1
(en)
*
|
2021-06-15 |
2024-01-18 |
Beijing Sinotau Bio-Pharmaceuticals Technology Co., Ltd. |
Anti-her3 antibody, antibody drug conjugate containing the same, and use thereof
|
|
CN117881431A
(zh)
|
2021-08-24 |
2024-04-12 |
昆山新蕴达生物科技有限公司 |
一种由可断裂连接子偶联的抗体偶联药物
|
|
AU2022361382A1
(en)
|
2021-10-05 |
2024-03-28 |
Amgen Inc. |
Fc-gamma receptor ii binding and glycan content
|
|
CN118401258A
(zh)
|
2021-12-09 |
2024-07-26 |
昆山新蕴达生物科技有限公司 |
一种亲和力改善的抗体-药物偶联物、其制备方法及应用
|
|
AU2023213783A1
(en)
|
2022-01-28 |
2024-08-15 |
Duality Biologics (Suzhou) Co., Ltd. |
Her3 antibody-drug conjugate and use thereof
|
|
AU2023228226A1
(en)
*
|
2022-03-03 |
2024-10-03 |
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. |
Her3 binding protein and use thereof
|
|
TW202400140A
(zh)
|
2022-04-27 |
2024-01-01 |
日商第一三共股份有限公司 |
抗體-藥物結合物與ezh1及/或ezh2抑制劑之組合
|
|
EP4514396A1
(en)
*
|
2022-04-29 |
2025-03-05 |
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. |
Antibody-drug conjugates and preparation methods and use thereof
|
|
WO2023215725A1
(en)
|
2022-05-02 |
2023-11-09 |
Fred Hutchinson Cancer Center |
Compositions and methods for cellular immunotherapy
|
|
WO2023218378A1
(en)
|
2022-05-11 |
2023-11-16 |
Daiichi Sankyo Company, Limited |
Combination of an antibody specific for a tumor antigen and a cd47 inhibitor
|
|
JP2026508145A
(ja)
|
2023-02-09 |
2026-03-10 |
ビーワン メディシンズ ワン ゲーエムベーハー |
自己安定化リンカーコンジュゲート
|
|
WO2024220916A1
(en)
|
2023-04-20 |
2024-10-24 |
Amgen Inc. |
Methods of determining relative unpaired glycan content
|
|
WO2024248123A1
(ja)
|
2023-06-02 |
2024-12-05 |
第一三共株式会社 |
抗ｈｅｒ３抗体－薬物コンジュゲートとｒａｓｇ１２ｃ阻害剤の組み合わせ
|
|
CN116444672B
(zh)
|
2023-06-13 |
2023-11-03 |
上海偌妥生物科技有限公司 |
人表皮生长因子3的抗体、其制备方法及其应用
|
|
TW202500198A
(zh)
|
2023-06-29 |
2025-01-01 |
瑞士商百濟神州瑞士有限責任公司 |
生物活性偶聯物、其製備方法及用途
|
|
CN121568721A
(zh)
|
2023-06-29 |
2026-02-24 |
广州百济神州生物制药有限公司 |
生物活性缀合物、其制备方法和其用途
|
|
WO2025005240A1
(ja)
|
2023-06-30 |
2025-01-02 |
第一三共株式会社 |
活性炭材料を使用する精製工程を含む抗体－薬物コンジュゲートの製造方法
|
|
WO2025038600A1
(en)
|
2023-08-14 |
2025-02-20 |
Amgen Inc. |
Methods for reducing yellow color
|
|
WO2025101820A1
(en)
|
2023-11-08 |
2025-05-15 |
Fred Hutchinson Cancer Center |
Compositions and methods for cellular immunotherapy
|
|
WO2025190404A1
(zh)
*
|
2024-03-14 |
2025-09-18 |
珠海普米斯生物科技有限公司 |
双特异性抗体、抗体药物偶联物及其应用
|